Baird Medical to Showcase Minimally Invasive Thyroid Solutions at Upcoming US Clinical Conferences
MWN-AI** Summary
Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD), a prominent player in the field of minimally invasive Microwave Ablation (MWA) technology, is set to participate in three significant clinical conferences this quarter, showcasing its innovative needle-based therapies for treating thyroid conditions. These events highlight Baird Medical's commitment to expanding its presence in the U.S. healthcare market and providing clinicians with advanced treatment options.
The conferences include the North American Society for Interventional Endocrinology (NASOIE) in Miami, FL on February 27-28, the North American Society for Interventional Thyroidology (NASIT) in Portland, OR on March 6-7, and the International Society of Innovative Technologies for Endocrine Surgery (ISITES) in Washington, D.C. from March 11-13. During these events, Baird Medical aims to engage directly with physicians, demonstrating the capabilities of its state-of-the-art technology that offers alternatives to traditional thyroid surgery, thus eliminating the need for scarring.
Mark Saxton, CEO of Baird Medical (US), emphasized the importance of these interactions, stating that they are essential for driving the adoption of minimally invasive procedures as the new standard of care. Baird Medical is focused not only on advancing surgical techniques but also on fostering collaborations with leading academic institutions to further enhance patient outcomes.
An FDA 510(k)-certified medical device company, Baird Medical has successfully implemented its solutions in over 30 prestigious hospitals and clinics across the United States, including renowned institutions like the Mayo Clinic and UCSF Medical Center. The company is also recognized as a market leader in China for thyroid microwave ablation devices and aims to expand its commercial footprint in over 20 countries worldwide. As Baird Medical continues to innovate and engage with the clinical community, its growth trajectory looks promising in the evolving landscape of minimally invasive medicine.
MWN-AI** Analysis
Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) is positioning itself prominently in the medical device sector with a focus on minimally invasive Microwave Ablation (MWA) technologies for treating thyroid conditions. The company's participation in upcoming clinical conferences, including NASOIE, NASIT, and ISITES, marks a strategic approach to enhance visibility among US clinicians and drive adoption of innovative therapies.
Given the growing trend towards minimally invasive surgical techniques, Baird Medical is well-poised to capture market share, primarily because such methods are increasingly regarded as the standard of care. The company's efforts to build direct relationships with leading interventionalists and surgeons at these conferences could facilitate the integration of its technologies into clinical practice, ultimately influencing the treatment landscape for thyroid conditions.
Investors should note that the current landscape is bolstered by an aging population and rising awareness of thyroid disorders, which further affirms the long-term viability of Baird Medical’s focus area. The company’s substantial presence in prestigious hospitals and clinics, including the Mayo Clinic and UCSF Medical Center, underscores its credibility and potential to expand its operations in the US market, following a similar trajectory in China.
However, prospective investors should remain cautious about potential risks and uncertainties mentioned in the company’s forward-looking statements. These may include regulatory challenges, competition within the medical device market, and overall economic conditions. Thus, it's advisable to consider these factors when assessing the investment potential of Baird Medical.
Overall, Baird Medical presents a promising opportunity within the health tech arena, with its innovative solutions aligned with current trends towards minimally invasive procedures. Investors seeking exposure to the medical technology sector may find it worthwhile to monitor Baird Medical’s strategic developments closely.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
NEW YORK, Feb. 19, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced its participation for three major clinical conferences this quarter. These events are pivotal to the company's expansion, providing U.S. clinicians direct access to its innovative needle-based therapies for thyroid conditions.
Baird Medical will join top interventionalists and surgeons to demonstrate how its proprietary technology treats benign nodules without the need for traditional surgery or scarring.
The Company will present its solutions at:
- North American Society for Interventional Endocrinology (NASOIE)
- February 27 – 28 | Miami, FL
- North American Society for Interventional Thyroidology (NASIT)
- March 6 – 7 | Portland, OR
- International Society of Innovative Technologies for Endocrine Surgery (ISITES)
- March 11 – 13 | Washington, D.C.
"We are on the ground at these events to show physicians exactly what our technology can do for their patients," said Mark Saxton, CEO of Baird Medical (US). "As minimally invasive options become the standard of care, building these direct relationships with the clinical community is how we drive adoption and grow our presence in the US market."
About Baird Medical
Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company will foster strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical's solutions have been used in over 30 prestigious hospitals and clinics across the United States, including Mayo Clinic, Tulane Medical Center, Columbia University Medical Center, UCSF Medical Center, Weill Cornell Medical Center, and The George Washington University Hospital. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide.
Forward-Looking Statements
This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.
Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (6) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled "Risk Factors" therein, and in ExcelFin's other filings with the SEC.
The foregoing list of factors is not exclusive. Additional information concerning certain of these, and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com
SOURCE BDMD
FAQ**
How does Baird Medical Investment Holdings Ltd (BDMD) plan to leverage its participation in the NASOIE, NASIT, and ISITES conferences to enhance its market adoption of minimally invasive microwave ablation technology for thyroid conditions?
What specific advantages does Baird Medical Investment Holdings Ltd (BDMD) believe its minimally invasive solutions provide over traditional surgical methods for treating benign thyroid nodules?
Given the increasing focus on precision medicine, how does Baird Medical Investment Holdings Ltd (BDMD) intend to foster strategic collaborations with academic institutions to advance its research and development efforts?
What strategies is Baird Medical Investment Holdings Ltd (BDMD) implementing to navigate potential regulatory challenges and market expansion risks in both the U.S. and international markets?
**MWN-AI FAQ is based on asking OpenAI questions about Baird Medical Investment Holdings Ltd (NASDAQ: BDMD).
NASDAQ: BDMD
BDMD Trading
-0.47% G/L:
$3.15 Last:
825,569 Volume:
$3.22 Open:
